| NCT05764239 | Efficacy and Safety of SYNB1934 in Patients With PKU (SYNPHENY-3) | TERMINATED | PHASE3 | 2023-07-05 | 2024-03-15 | 2024-03-15 |
| NCT05462132 | Safety, Tolerability and Pharmacodynamics of SYNB1353 in Healthy Adult Volunteers | COMPLETED | PHASE1 | 2022-07-07 | 2022-11-27 | 2022-11-27 |
| NCT05377112 | Safety, Tolerability, and Pharmacodynamics of SYNB8802v1 in Subjects With History of Gastric Bypass Surgery or Short-bowel Syndrome | COMPLETED | EARLY_PHASE1 | 2022-03-29 | 2022-12-07 | 2022-12-07 |
| NCT04984525 | Safety and Tolerability of SYNB1934 in Healthy Adult Volunteers | COMPLETED | PHASE1 | 2021-07-02 | 2021-12-10 | 2021-12-10 |
| NCT04629170 | Safety and Tolerability of SYNB8802 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria | COMPLETED | PHASE1 | 2020-11-04 | 2023-01-17 | 2023-01-17 |
| NCT04534842 | Efficacy and Safety of SYNB1618 and SYNB1934 in Adult Patients With Phenylketonuria | COMPLETED | PHASE2 | 2020-08-25 | 2022-10-07 | 2022-10-07 |
| NCT04167137 | Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants | TERMINATED | PHASE1 | 2019-12-12 | 2021-12-09 | 2021-12-09 |
| NCT03516487 | Safety and Tolerability of SYNB1618 in Healthy Adult Volunteers and Adult Subjects With Phenylketonuria | COMPLETED | PHASE1, PHASE2 | 2018-04-17 | 2019-06-21 | 2019-06-21 |
| NCT03447730 | Safety, Tolerability and Pharmacodynamics of SYNB1020 | TERMINATED | PHASE1, PHASE2 | 2018-03-19 | 2019-07-19 | 2019-07-19 |
| NCT03179878 | Safety and Tolerability of SYNB1020-CP-001 | COMPLETED | PHASE1 | 2017-06-16 | 2018-04-11 | 2017-11-02 |